KAI Pharmaceuticals Announces Late Breaker Poster Presentation of KAI-4169 ... - MarketWatch (press release) PDF Print
MarketWatch (press release)
Geoffrey A. Block, MD, Director of Clinical Research, Denver Nephrology, and a principal investigator in the Phase 2 study, stated, "KAI-4169 represents a new innovative therapeutic approach for the treatment of CKD-MBD. There is a consensus among

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.